-
Something wrong with this record ?
Diagnostic and prognostic value of placental growth factor serum concentration in clear cell renal cell carcinoma
M. Cechova, M. Chocholaty, M. Babjuk, T. Zima, K. Havlova, M. Koldova, M. Schmidt, M. Kalousova
Language English Country Czech Republic
Document type Journal Article
NLK
Directory of Open Access Journals
from 2001
Free Medical Journals
from 1998
Medline Complete (EBSCOhost)
from 2007-06-01
ROAD: Directory of Open Access Scholarly Resources
from 2001
PubMed
33612835
DOI
10.5507/bp.2021.003
Knihovny.cz E-resources
- MeSH
- Biomarkers MeSH
- Carcinoma, Renal Cell * diagnosis MeSH
- Humans MeSH
- Neoplasm Recurrence, Local diagnosis MeSH
- Kidney Neoplasms * MeSH
- Placenta Growth Factor MeSH
- Prognosis MeSH
- Prospective Studies MeSH
- Check Tag
- Humans MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
BACKGROUND AND AIM: Placental Growth Factor (PlGF) plays a crucial role in angiogenesis and was identified as a potential prognostic biomarker in various types of cancer. Therefore, we evaluated the diagnostic accuracy and prognostic value of PlGF serum concentration in patients with clear cell renal cell carcinoma (ccRCC). PATIENTS AND METHODS: A total of 49 patients subjected to partial or radical nephrectomy for ccRCC [localized without relapse (lccRCC; n=31), localized with later relapse (rccRCC; n=8), primary metastatic cancer (mccRCC; n=10); median of follow-up 4.4 years] were enrolled in a prospective study to assess the significance of PlGF serum concentration. PlGF was measured prior to surgery and 3 months postoperatively. Our control group consisted of 38 healthy subjects. RESULTS: PlGF serum concentration was significantly higher in ccRCC compared to controls (P=0.002). The cut-off value of PlGF concentration for the risk of ccRCC was determined at 12.71 pg/mL (AUC=0.729; P=0.0001). Prior to surgery, among ccRCC subgroups, significantly higher PlGF concentration was detected in mccRCC compared to lccRCC (P=0.002). Postoperatively, we observed a tendency to higher PlGF serum concentration in rccRCC compared to lccRCC subgroup, however without significance (P=0.17). The cut-off value for the risk of relapse was 11.41 pg/mL (AUC=0.792; P=0.0003). In subjects with localized ccRCC with PlGF concentration below 11.41 pg/mL 3-years cancer specific survival was 93% compared to 61% in subject with concentration above the cut-off value (P=0.018). CONCLUSION: Based on our findings, PlGF serum concentration seems to be a useful biomarker in diagnostics and prediction of prognosis in ccRCC.
References provided by Crossref.org
Literatura
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22007888
- 003
- CZ-PrNML
- 005
- 20220429095119.0
- 007
- ta
- 008
- 220309s2021 xr d f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.5507/bp.2021.003 $2 doi
- 035 __
- $a (PubMed)33612835
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xr
- 100 1_
- $a Koldová, Markéta $7 xx0272359 $u Department of Urology, University Hospital Motol and 2nd Faculty of Medicine, Charles University, Prague, Czech Republic
- 245 10
- $a Diagnostic and prognostic value of placental growth factor serum concentration in clear cell renal cell carcinoma / $c M. Cechova, M. Chocholaty, M. Babjuk, T. Zima, K. Havlova, M. Koldova, M. Schmidt, M. Kalousova
- 504 __
- $a Literatura
- 520 9_
- $a BACKGROUND AND AIM: Placental Growth Factor (PlGF) plays a crucial role in angiogenesis and was identified as a potential prognostic biomarker in various types of cancer. Therefore, we evaluated the diagnostic accuracy and prognostic value of PlGF serum concentration in patients with clear cell renal cell carcinoma (ccRCC). PATIENTS AND METHODS: A total of 49 patients subjected to partial or radical nephrectomy for ccRCC [localized without relapse (lccRCC; n=31), localized with later relapse (rccRCC; n=8), primary metastatic cancer (mccRCC; n=10); median of follow-up 4.4 years] were enrolled in a prospective study to assess the significance of PlGF serum concentration. PlGF was measured prior to surgery and 3 months postoperatively. Our control group consisted of 38 healthy subjects. RESULTS: PlGF serum concentration was significantly higher in ccRCC compared to controls (P=0.002). The cut-off value of PlGF concentration for the risk of ccRCC was determined at 12.71 pg/mL (AUC=0.729; P=0.0001). Prior to surgery, among ccRCC subgroups, significantly higher PlGF concentration was detected in mccRCC compared to lccRCC (P=0.002). Postoperatively, we observed a tendency to higher PlGF serum concentration in rccRCC compared to lccRCC subgroup, however without significance (P=0.17). The cut-off value for the risk of relapse was 11.41 pg/mL (AUC=0.792; P=0.0003). In subjects with localized ccRCC with PlGF concentration below 11.41 pg/mL 3-years cancer specific survival was 93% compared to 61% in subject with concentration above the cut-off value (P=0.018). CONCLUSION: Based on our findings, PlGF serum concentration seems to be a useful biomarker in diagnostics and prediction of prognosis in ccRCC.
- 650 _2
- $a biologické markery $7 D015415
- 650 12
- $a karcinom z renálních buněk $x diagnóza $7 D002292
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a nádory ledvin $7 D007680
- 650 _2
- $a lokální recidiva nádoru $x diagnóza $7 D009364
- 650 _2
- $a placentární růstový faktor $7 D000072483
- 650 _2
- $a prognóza $7 D011379
- 650 _2
- $a prospektivní studie $7 D011446
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Chocholatý, Matúš $7 xx0121519 $u Department of Urology, University Hospital Motol and 2nd Faculty of Medicine, Charles University, Prague, Czech Republic
- 700 1_
- $a Babjuk, Marko, $d 1961- $7 jn20020716353 $u Department of Urology, University Hospital Motol and 2nd Faculty of Medicine, Charles University, Prague, Czech Republic
- 700 1_
- $a Zima, Tomáš, $d 1966- $7 jn20000620440 $u Institute of Medical Biochemistry and Laboratory Diagnostics, General University Hospital and 1st Faculty of Medicine, Charles University, Prague, Czech Republic
- 700 1_
- $a Havlová, Klára $7 xx0184887 $u Department of Urology, University Hospital Motol and 2nd Faculty of Medicine, Charles University, Prague, Czech Republic
- 700 1_
- $a Koldová, Markéta $7 xx0272359 $u Department of Urology, University Hospital Motol and 2nd Faculty of Medicine, Charles University, Prague, Czech Republic
- 700 1_
- $a Schmidt, Marek $7 xx0105483 $u Department of Urology, University Hospital Motol and 2nd Faculty of Medicine, Charles University, Prague, Czech Republic
- 700 1_
- $a Kalousová, Marta, $d 1974- $7 mzk2005318016 $u Institute of Medical Biochemistry and Laboratory Diagnostics, General University Hospital and 1st Faculty of Medicine, Charles University, Prague, Czech Republic
- 773 0_
- $w MED00012606 $t Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia $x 1213-8118 $g Roč. 165, č. 4 (2021), s. 375-379
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/33612835 $y Pubmed
- 910 __
- $a ABA008 $b A 1502 $c 958 $y p $z 0
- 990 __
- $a 20220309 $b ABA008
- 991 __
- $a 20220429095111 $b ABA008
- 999 __
- $a ok $b bmc $g 1773018 $s 1159081
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 165 $c 4 $d 375-379 $e 20210222 $i 1213-8118 $m Biomedical papers of the Medical Faculty of the University Palacký, Olomouc Czech Republic $n Biomed. Pap. Fac. Med. Palacký Univ. Olomouc Czech Repub. (Print) $x MED00012606
- LZP __
- $b NLK118 $a Pubmed-20220309